Hopstem Bio Completes $40 Million B Round for Neural Stem Cell Therapy
publication date: Nov 8, 2021
Hopstem Biotech, a China-US stem-cell therapy company, completed a near $40 million B financing, led by an unnamed VC/PE with participation by Lilly Asia Ventures and YuanBio Venture Capital. The company's lead product is an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product. Hopstem has built a neural differentiation platform and established a patented method to reprogram iPSC cells. Founded in 2017 by neuroscientists and stem-cell biologists from Johns Hopkins, Hopstem has operations in Hangzhou and Baltimore. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.